Perrigo (NYSE:PRGO) Director Jeffrey C. Smith acquired 250,000 shares of Perrigo stock in a transaction dated Tuesday, May 15th. The stock was bought at an average price of $75.21 per share, for a total transaction of $18,802,500.00. Following the completion of the purchase, the director now owns 528 shares of the company’s stock, valued at approximately $39,710.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Perrigo traded up $0.18, reaching $75.86, during midday trading on Thursday, MarketBeat.com reports. The company’s stock had a trading volume of 693,200 shares, compared to its average volume of 1,108,458. Perrigo has a fifty-two week low of $75.66 and a fifty-two week high of $76.20. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.08 and a quick ratio of 1.48. The stock has a market cap of $10.46 billion, a PE ratio of 15.39, a P/E/G ratio of 1.77 and a beta of 0.77.
Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Tuesday, May 8th. The company reported $1.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.12. Perrigo had a return on equity of 11.93% and a net margin of 2.59%. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same period last year, the firm earned $1.05 earnings per share. Perrigo’s quarterly revenue was up 1.9% on a year-over-year basis. research analysts expect that Perrigo will post 5.25 earnings per share for the current fiscal year.
Several analysts have recently issued reports on PRGO shares. Canaccord Genuity reiterated a “buy” rating and issued a $100.00 price objective on shares of Perrigo in a research note on Wednesday, January 17th. Cantor Fitzgerald set a $107.00 price objective on Perrigo and gave the company a “buy” rating in a research note on Friday, January 19th. Berenberg Bank started coverage on Perrigo in a research note on Thursday, February 1st. They issued a “buy” rating and a $117.00 price objective on the stock. Oppenheimer reiterated a “buy” rating and issued a $98.00 price objective on shares of Perrigo in a research note on Tuesday, February 27th. Finally, JPMorgan Chase reiterated a “neutral” rating and issued a $83.00 price objective (up from $82.00) on shares of Perrigo in a research note on Monday, March 5th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $93.06.
A number of institutional investors have recently bought and sold shares of PRGO. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Perrigo by 356.7% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,436,621 shares of the company’s stock worth $125,216,000 after purchasing an additional 1,122,068 shares during the last quarter. Ceredex Value Advisors LLC purchased a new position in shares of Perrigo during the first quarter worth about $81,786,000. Victory Capital Management Inc. grew its holdings in shares of Perrigo by 90.5% during the fourth quarter. Victory Capital Management Inc. now owns 2,046,980 shares of the company’s stock worth $178,414,000 after purchasing an additional 972,210 shares during the last quarter. Systematic Financial Management LP purchased a new position in shares of Perrigo during the fourth quarter worth about $36,866,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Perrigo by 289.2% during the fourth quarter. Renaissance Technologies LLC now owns 448,408 shares of the company’s stock worth $39,083,000 after purchasing an additional 333,200 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.